About: Consideration of Pannexin 1 channels in COVID-19 pathology and treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Consideration of Pannexin 1 channels in COVID-19 pathology and treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Consideration of Pannexin 1 channels in COVID-19 pathology and treatment
Creator	Koval, Michael Good, Miranda Isakson, Brant Johnstone, Scott Laubach, Victor Lohman, Alexander Ng, Chen Penuela, Silvia Sanchez-Arias, Juan Swayne, Leigh Wolpe, Abigail
source	Medline; PMC
abstract	Pannexin1 (PANX1) is a ubiquitously expressed, channel-forming protein found in a number of tissues thoughout the body (e.g. lung, vasculature, liver, central nervous system, immune system) that is important in many key physiological and immune responses. PANX1 channels passively flux ATP (predominantly), multiple metabolites, and likely other small anions. PANX1 channels regulate inflammation and host responses to several pathogens, including viruses. While there is currently no evidence suggesting novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and PANX1 directly interact, there is an urgent need for therapeutic strategies, especially those targeting the hyper-inflammation and cytokine storm that occurs in severe cases of COVID-19. Here we argue that PANX1, and drugs known to target PANX1 (including the FDA-approved drug probenecid), should be the focus of further investigation in the context of SARS-CoV-2 infection and its associated pathology in COVID-19 patients.
has issue date	2020-07-01(xsd:dateTime)
bibo:doi	10.1152/ajplung.00146.2020
bibo:pmid	32519892
has license	no-cc
schema:url	https://doi.org/10.1152/ajplung.00146.2020
resource representing a document's title	Consideration of Pannexin 1 channels in COVID-19 pathology and treatment
has PubMed Central identifier	PMC7347959
has PubMed identifier	32519892
schema:publication	Am J Physiol Lung Cell Mol Physiol
resource representing a document's body	covid:PMC7347959#body_text
is schema:about of	named entity 'lung' named entity 'IL-6' named entity 'SARS-CoV-2' named entity 'virus' named entity 'reperfusion injury' named entity 'tenofovir' named entity 'anions' named entity 'purinergic receptors' named entity 'oseltamivir' named entity 'secretion' named entity 'PANX1' named entity 'inflammatory responses' named entity 'inflammatory responses' named entity 'dyspnea' named entity 'virus' named entity 'ACE2' named entity 'PANX1' named entity 'probenecid' named entity 'cell types' named entity 'lung' named entity 'therapeutic strategies' named entity 'peptide' named entity 'inflammation' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'PANX1' named entity 'receptor' named entity 'PANX1' named entity 'caveolin' named entity 'gout' named entity 'viruses' named entity 'COVID-19' named entity 'NIH' named entity 'reduces inflammation' named entity 'viral load' named entity 'antiviral' named entity 'PANX1' named entity 'influenza' named entity 'inflammation' named entity 'life cycles' named entity 'PANX1' named entity 'coronavirus infection' named entity 'physiological' named entity 'spironolactone' named entity 'COVID' named entity 'IL-1β' named entity 'hyperinflammation' named entity 'probenecid' named entity 'vasculature' named entity 'SARS-CoV-2' named entity 'FDA' named entity 'vascular inflammation' named entity 'protein' named entity 'PANX1' named entity 'ATP' named entity 'endosomes' named entity 'endothelial cell' named entity 'P2X7 receptors' named entity 'microvasculature' named entity 'spironolactone' named entity 'spironolactone' named entity 'TRPV4' named entity 'oxygen therapy' named entity 'ARDS' named entity 'nucleotide analog' named entity 'SARS-CoV-2' named entity 'nucleotide' named entity 'extracellular' named entity 'liver cell' named entity 'intracellular' named entity 'pharmacologically' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software